<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><title>THE "NEW" PROSTATE CANCER INFOLINK</title><style><!--
/* Font Definitions */
@font-face
{font-family:Helvetica;
panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Cambria;
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Georgia;
panose-1:2 4 5 2 5 4 5 2 3 3;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
h1
{mso-style-priority:9;
mso-style-link:"Heading 1 Char";
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:24.0pt;
font-family:"Times New Roman","serif";
font-weight:bold;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p
{mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
span.Heading1Char
{mso-style-name:"Heading 1 Char";
mso-style-priority:9;
mso-style-link:"Heading 1";
font-family:"Cambria","serif";
color:#365F91;
font-weight:bold;}
span.EmailStyle19
{mso-style-type:personal;
font-family:"Calibri","sans-serif";
color:#1F497D;}
span.EmailStyle20
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link=blue vlink=purple><div class=WordSection1><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Hi </span><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>all:</span><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Below is a link to an interesting article wrt Brachy and other treatments for high risk PCa patients.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>I have queried doctors who treat PCa in Kitchener, Hamilton, & Toronto about </span><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>doing LDR & HDR with boost brachy treatments</span><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>The last paragraph in the article (copied below) indicates the challenge that patients face in getting information on the full spectrum of available treatments.<o:p></o:p></span></p><p class=MsoNormal>Sadly, <a href="http://www.brachyjournal.com/article/S1538-4721(17)30004-1/abstract" target="_blank">a recent analysis of the National Cancer Database</a> showed that utilization of brachy boost therapy for high-risk patients declined precipitously from 28 percent in 2004 to 11 percent in 2013. If a patient sees anyone other than the first urologist, he often only sees a single radiation oncologist who only informs him about IMRT. In most parts of the US, there is a dearth of experienced brachytherapists.<o:p></o:p></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal>Take care,<o:p></o:p></p><p class=MsoNormal>Glen<o:p></o:p></p><p><b><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:blue'>Glen N. Tolhurst P.Eng. MBA</span></b><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:black'><o:p></o:p></span></p><p><b><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:blue'>Chair PCCN Waterloo- Wellington</span></b><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:black'><o:p></o:p></span></p><p><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:black'>web site: </span><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:black'><a href="http://pccn-waterloo-wellington.ca/" id=LPlnk825412><span style='font-size:14.0pt;font-family:"Arial","sans-serif"'>http://pccn-waterloo-wellington.ca/</span></a></span><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:black'> </span><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:black'><o:p></o:p></span></p><p><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:black'>e-mail: </span><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:black'><a href="mailto:info@pccn-waterloo-wellington.ca"><span style='font-size:14.0pt;font-family:"Arial","sans-serif"'>info@pccn-waterloo-wellington.ca</span></a></span><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:black'> </span><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:black'><o:p></o:p></span></p><p><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:black'>answering service 226-240-9264</span><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:black'><o:p></o:p></span></p><p><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:red'>Direct contact via:</span><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:black'><o:p></o:p></span></p><p><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:black'>Tel (519) 826-0716 </span><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:black'><o:p></o:p></span></p><p><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:black'>Cell (519) 994-4536</span><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:black'><o:p></o:p></span></p><p><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:black'>e-mail: </span><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:black'><a href="mailto:Glen46Nor@gmail.com"><span style='font-size:14.0pt;font-family:"Arial","sans-serif"'>Glen46Nor@gmail.com</span></a><o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><o:p> </o:p></p><div style='margin-left:24.0pt;margin-right:24.0pt' id=emailbody><table class=MsoNormalTable border=0 cellpadding=0 width="100%" style='width:100.0%'><tr><td width="99%" valign=top style='width:99.0%;padding:0cm 0cm 0cm 0cm'><h1 style='margin:0cm;margin-bottom:.0001pt'><a href="https://prostatecancerinfolink.net" title="(https://prostatecancerinfolink.net)"><span style='font-size:16.5pt;font-family:"Arial","sans-serif";color:#888888;font-weight:normal;text-decoration:none'>The Prostate Cancer InfoLink</span></a> <o:p></o:p></h1></td><td width="1%" style='width:1.0%;padding:0cm 0cm 0cm 0cm'></td></tr></table><div class=MsoNormal align=center style='text-align:center;line-height:140%'><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia","serif";color:black'><hr size=2 width="100%" align=center></span></div><table class=MsoNormalTable border=0 cellpadding=0 id=itemcontentlist><tr><td style='padding:.75pt .75pt .75pt .75pt'><p style='mso-margin-top-alt:12.0pt;margin-right:0cm;margin-bottom:2.25pt;margin-left:0cm;line-height:16.8pt'><a name=1></a><a href="http://feedproxy.google.com/~r/TheProstateCancerInfolink/~3/EgfoaPePYR4/?utm_source=feedburner&utm_medium=email"><b><span style='font-size:13.5pt;font-family:"Arial","sans-serif";color:#000099;text-decoration:none'>Brachy boost therapy and surgery extend survival about the same in high-risk patients, but brachy boost does more</span></b></a> <o:p></o:p></p><p style='mso-margin-top-alt:6.75pt;margin-right:0cm;margin-bottom:2.25pt;margin-left:0cm;line-height:140%'><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia","serif";color:#555555'>Posted: 15 Mar 2018 05:46 AM PDT<o:p></o:p></span></p><div><p class=MsoNormal style='line-height:140%'><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia","serif";color:black'>Two retrospective studies were published in the last week, and they had some similar findings, but some dissimilar things to say about which treatment is best for high-risk prostate cancer. The three therapies they looked at were the combination of brachytherapy and external beam radiation (brachy boost therapy or BBT), external beam therapy alone (EBRT), […]<o:p></o:p></span></p></div></td></tr></table><p class=MsoNormal style='line-height:140%'><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia","serif";color:black;display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=1 cellpadding=0 width="100%" style='width:100.0%;border:none;border-top:solid #999999 1.0pt' id=footer><tr><td style='border:none;padding:3.0pt .75pt .75pt .75pt'><p class=MsoNormal style='mso-margin-top-alt:0cm;margin-right:4.5pt;margin-bottom:14.4pt;margin-left:0cm'><span style='font-size:8.5pt;font-family:"Helvetica","sans-serif";color:#333333'>You are subscribed to email updates from <a href="https://prostatecancerinfolink.net">THE "NEW" PROSTATE CANCER INFOLINK</a>..<o:p></o:p></span></p></td><td valign=top style='border:none;padding:3.0pt .75pt .75pt .75pt'><p class=MsoNormal align=right style='mso-margin-top-alt:0cm;margin-right:4.5pt;margin-bottom:14.4pt;margin-left:0cm;text-align:right'><span style='font-size:8.5pt;font-family:"Helvetica","sans-serif";color:#333333'>Email delivery powered by Google<o:p></o:p></span></p></td></tr><tr><td colspan=2 style='border:none;padding:3.0pt .75pt .75pt .75pt'><p class=MsoNormal style='mso-margin-top-alt:0cm;margin-right:4.5pt;margin-bottom:14.4pt;margin-left:0cm'><span style='font-size:8.5pt;font-family:"Helvetica","sans-serif";color:#333333'>Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States<o:p></o:p></span></p></td></tr></table><p class=MsoNormal><o:p> </o:p></p></div></div></body></html>